Linked Life Data

15261557

Source:http://linkedlifedata.com/resource/pubmed/id/15261557

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2004-7-20
pubmed:abstractText
Evidence for the effectiveness of immunosuppressive agents in MS is scanty. There are few good quality trials; most have methodological limitations, such as a small sample size and short duration. Moreover, there is no consistency in treatment regimes, patient groups or outcome measures and the clinical benefits remain unclear. Although azathioprine appears to reduce the relapse rate in MS patients, its effect on disability progression has not been demonstrated. Methotrexate may alter the course of disease favourably in patients with progressive MS, but the evidence is again sparse.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0022-510X
pubmed:author
pubmed:copyrightInfo
Copyright 2004 Elsevier B.V.
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
223
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
29-34
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Azathioprine and methotrexate in multiple sclerosis.
pubmed:affiliation
Instituto de Neurociencias, Servicio de Neurología, Hospital Regional Universitario Carlos Haya, Málaga, Spain. oscar.fernandez.sspa@juntadeandalucia.es
pubmed:publicationType
Journal Article, Review